©The Author(s) 2026.
World J Gastroenterol. Jan 28, 2026; 32(4): 115040
Published online Jan 28, 2026. doi: 10.3748/wjg.v32.i4.115040
Published online Jan 28, 2026. doi: 10.3748/wjg.v32.i4.115040
Table 1 Description of study population, n (%)
| Variables | Antibiotics exposure (n = 372) | Non-antibiotics exposure (n = 1613) | P value |
| Age, year, median IQR | 50.00 (33.00, 62.00) | 37.00 (25.00, 53.00) | < 0.001 |
| Gender | 0.020 | ||
| Male | 264 (20.5) | 1024 (79.5) | |
| Female | 108 (15.9) | 571 (84.1) | |
| Subtypes | < 0.001 | ||
| UC | 192 (23.8) | 615 (76.2) | |
| CD | 180 (15.3) | 998 (84.7) | |
| Length of stay, day(s), median (IQR) | 11.00 (7.00, 14.00) | 1.00 (1.00, 4.00)1 | < 0.001 |
| Hospitalization costs, 1000 CNY, median (IQR) | 8.94 (5.81, 15.74) | 3.15 (0.33, 6.14) | < 0.001 |
- Citation: Zeng W, Zhang WK, Xu D, He K, Huang YP, Liu YX, Yang HF. Antibiotic consumption of inpatients with inflammatory bowel disease during 2015-2024 and future prediction: Evidence from a general hospital. World J Gastroenterol 2026; 32(4): 115040
- URL: https://www.wjgnet.com/1007-9327/full/v32/i4/115040.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i4.115040